Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 10:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 38 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Bromfenac Clear all
Completed No phase listed Observational Accepts healthy volunteers

Bromday Versus Nevanac Eye Drops to Control Pain Following Photorefractive Keratectomy

NCT01475877
View directory record Official record
Conditions
Myopia
Interventions
Bromfenac
Drug
Lead sponsor
Virdi Eye Clinic
Other
Eligibility
21 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Rock Island, Illinois
Source: ClinicalTrials.gov public record
Updated May 3, 2016 · Synced Oct 20, 2026, 10:18 AM EDT
Completed Phase 3 Interventional Results available

Efficacy Study of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract Surgery

NCT00853970
View directory record Official record
Conditions
Pain, Inflammation
Interventions
Bromfenac Ophthalmic Solution, Placebo Comparator
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Jan 25, 2013 · Synced Oct 20, 2026, 10:18 AM EDT
Completed Phase 4 Interventional Results available

Prophylactic Treatment: Lessdrops™ vs Standard Drops Regimen

NCT03578276
View directory record Official record
Conditions
Cataract
Interventions
Pred-Gati-Brom, Prednisolone acetate 1% ophthalmic suspension, Gatifloxacin Ophthalmic, Bromfenac 0.075% Oph Solution
Drug
Lead sponsor
Carolina Eyecare Physicians, LLC
Other
Eligibility
50 Years to 99 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Mt. Pleasant, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 10, 2022 · Synced Oct 20, 2026, 10:18 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Comparing Optical Coherence Tomography (OCT) and Visual Acuity Outcomes in Subjects Undergoing Cataract Surgery, Who Receive Xibrom Ophthalmic Solution and Standard Presurgical Care vs. Xibrom Ophthalmic Solution Plus Prednisolone Acetate 1% and Standard Presurgical Care

NCT00698724
View directory record Official record
Conditions
Cataracts
Interventions
Xibrom, and Optive, Xibrom and Pred Forte
Drug
Lead sponsor
Bp Consulting, Inc
Network
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Tarpon Springs, Florida
Source: ClinicalTrials.gov public record
Updated Jun 10, 2009 · Synced Oct 20, 2026, 10:18 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Safety Study of Bromfenac Ophthalmic Solution in Subjects With Diffuse Diabetic Macular Edema (DME) Refractory to Laser

NCT00491166
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Bromfenac ophthalmic solution
Drug
Lead sponsor
Ophthalmic Consultants of Boston
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 25, 2007 · Synced Oct 20, 2026, 10:18 AM EDT
Completed Phase 4 Interventional

Randomized, Double Blind Trial of Bromfenac BID (0.09%) as an Adjunct to Argon Laser Therapy in the Treatment of Diabetic Macular Edema.

NCT00758628
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Bromefenac, Blink
Drug
Lead sponsor
Bp Consulting, Inc
Network
Eligibility
18 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
140 East 80th Street New York, NY 10075, New York
Source: ClinicalTrials.gov public record
Updated Sep 4, 2009 · Synced Oct 20, 2026, 10:18 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Pain Reduction With Topical Bromfenac Versus Artificial Tear After Intravitreal Injection.

NCT06130384
View directory record Official record
Conditions
Pain, Intravitreal Injection, Pain, Acute
Interventions
Use of bromfenac 0.09% to reduce intravitreal injection pain, Use of artificial tears to reduce intravitreal injection pain
Drug
Lead sponsor
Wills Eye
Other
Eligibility
18 Years to 99 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
4
States / cities
Boston, Massachusetts • Bethlehem, Pennsylvania • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2024 · Synced Oct 20, 2026, 10:18 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery

NCT00703781
View directory record Official record
Conditions
Cataract
Interventions
bromfenac ophthalmic solution, placebo
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Oct 20, 2026, 10:18 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Aqueous Concentrations and PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% in Cataract Patients: Trough Drug Effects

NCT00469690
View directory record Official record
Conditions
Cataract
Interventions
Acular, Xibrom
Drug
Lead sponsor
Innovative Medical
Industry
Eligibility
21 Years and older
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Wilkes-Barre, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 20, 2008 · Synced Oct 20, 2026, 10:18 AM EDT
Terminated No phase listed Observational

Cross-linking of Corneal Collagen (CXL) With Ultraviolet-A in Asymmetric Corneas

NCT01189864
View directory record Official record
Conditions
Keratoconus, Ectasia, Degeneration
Interventions
Ciprofloxicin or Vigamox or other., Nonsteroidal (Acular, Acuvail, Voltaren Xibrom, etc), Steroid (FML, Pred Forte, Flarex, etc.)
Drug
Lead sponsor
Cxlusa
Industry
Eligibility
12 Years and older
Enrollment
3,493 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
16
States / cities
Scottsdale, Arizona • Laguna Hills, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2018 · Synced Oct 20, 2026, 10:18 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Comparison of Post Phacoemulsification Aqueous Flare in Patients Using Ketorolac 0.45% 2 Times Daily (BID) and Bromfenac 0.09% 2 Times Daily (BID)

NCT01023724
View directory record Official record
Conditions
Post Operative Anterior Chamber Inflammation (Flare)
Interventions
Ketorolac Tromethamine 0.45%, Bromfenac 0.09%
Drug
Lead sponsor
Bucci Laser Vision Institute
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Wilkes-Barre, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 26, 2011 · Synced Oct 20, 2026, 10:18 AM EDT
Completed Phase 4 Interventional

Treatment of Acute Pseudophakic Cystoid Macular Edema: Bromfenac 0.09% Versus Diclofenac Sodium 0.1% Versus Ketorolac Tromethamine 0.5%

NCT00595543
View directory record Official record
Conditions
Acute Pseudophakic Cystoid Macular Edema
Interventions
Bromfenac, Ketorolac, Diclofenac
Drug
Lead sponsor
Bp Consulting, Inc
Network
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 19, 2009 · Synced Oct 20, 2026, 10:18 AM EDT
Terminated No phase listed Observational

Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas (2)

NCT01097447
View directory record Official record
Conditions
Keratoconus, Ectasia, Degeneration
Interventions
Not listed
Lead sponsor
Cxlusa
Industry
Eligibility
8 Years and older
Enrollment
2,619 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
5
States / cities
San Diego, California • Littleton, Colorado • Hoffman Estates, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Oct 20, 2026, 10:18 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of Topical Bromfenac Versus Placebo to Treat Ocular Inflammation After Cataract Surgery

NCT00198445
View directory record Official record
Conditions
Postoperative Complications, Cataract
Interventions
Bromfenac, Placebo
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
39
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Irvine, California + 34 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2013 · Synced Oct 20, 2026, 10:18 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of an Ophthalmic Solution in Dry Eye Disease

NCT00758784
View directory record Official record
Conditions
Dry Eye Disease
Interventions
bromfenac ophthalmic solution 0.06%
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Sep 14, 2020 · Synced Oct 20, 2026, 10:18 AM EDT
Completed Phase 3 Interventional Results available

A Dose Ranging Study to Evaluate Safety and Efficacy of Bromfenac Ophthalmic Solution in Dry Eye Disease

NCT01212471
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
Bromfenac Ophthalmic Solution A, Bromfenac Ophthalmic Solution B, Placebo Comparator
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Sep 4, 2020 · Synced Oct 20, 2026, 10:18 AM EDT
Completed Phase 4 Interventional

Bromfenac BID Plus Prednisolone Acetate BID Versus Bromfenac BID Plus Prednisolone QID for the Prevention of Cystoid Macular Edema and Retinal Thickening

NCT00469781
View directory record Official record
Conditions
Cystoid Macular Edema,, Retinal Thickening
Interventions
2. Xibrom (Bromfenac), 1. Pred Forte
Drug
Lead sponsor
Center For Excellence In Eye Care
Other
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 25, 2008 · Synced Oct 20, 2026, 10:18 AM EDT
Completed Phase 4 Interventional

Comparing Post-intravitreal Injection Pain Scores Using Loteprednol, Bromfenac Sodium, and Artificial Tears Over a 24-hour Period

NCT07090044
View directory record Official record
Conditions
Vein Occlusion, Macular Degeneration Choroidal Neovascularization, Macular Edema, Diabetic Retinopathy
Interventions
Bromfenac Sodium 0.07%, Loteprednol Etabonate 0.38% Ophthalmic Gel/Jelly, Propylene Glycol Preservative-free Artificial Tears
Drug
Lead sponsor
Retina Research Institute, LLC
Other
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Oct 20, 2026, 10:18 AM EDT
Completed Phase 4 Interventional Results available

Control of Pain in Intravitreal Injections Using Topical NSAIDs

NCT04343222
View directory record Official record
Conditions
Intravitreal Injections, IVI
Interventions
Bromfenac, Artificial tears
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 12, 2023 · Synced Oct 20, 2026, 10:18 AM EDT
Completed Phase 2 Interventional

Combination Ranibizumab and Bromfenac for Neovascular Age-related Macular Degeneration

NCT00805233
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
combination ranibizumab + bromfenac, ranibizumab injection alone
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 22, 2011 · Synced Oct 20, 2026, 10:18 AM EDT
Completed Phase 4 Interventional

Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery

NCT05626478
View directory record Official record
Conditions
Corneal Edema, Corneal Defect, Anterior Chamber Inflammation, Ocular Pain, Corneal Staining, Visual Outcome, CME - Cystoid Macular Edema
Interventions
Dextenza 0.4Mg Ophthalmic Insert, Prednisolone Acetate 1% Oph Susp, Prolensa 0.07% Ophthalmic Solution
Drug
Lead sponsor
Nicole Fram M.D.
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 20, 2026, 10:18 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Comparison of Peak Aqueous Penetration of Acuvail (Ketorolac 0.45%), Xibrom (Bromfenac 0.09%), and Nevanac (Nepafenac 0.1%)in Patients Undergoing Phacoemulsification

NCT01001806
View directory record Official record
Conditions
Cataracts
Interventions
Ketorolac Tromethamine 0.45%, bromfenac 0.09%, nepafenac 0.1%
Drug
Lead sponsor
Frank A. Bucci, Jr., M.D.
Other
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Wilkes-Barre, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 3, 2011 · Synced Oct 20, 2026, 10:18 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Topical Bromfenac Ophthalmic Solution vs. Placebo in Subjects With Allergic Conjunctivitis

NCT00423007
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Bromfenac, Placebo
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
10 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Mar 14, 2013 · Synced Oct 20, 2026, 10:18 AM EDT